Tests a heart-artery guided treatment plan in heart attack patients with multiple narrowed arteries
Compares a flow-guided artery treatment strategy with standard care in adults with heart attack.
Plain-language title generated from the registry record
Registry title: The FAVOR V AMI Trial
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who recently had a heart attack of the ST-elevation type (STEMI) and also have narrowed arteries in other parts of the heart.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- STEMI within the last 30 days. The artery that caused the heart attack was successfully opened by PCI. At least 1 other narrowed artery lesion (50%-90% narrowing, vessel at least 2.5 mm wide) must be present.
- Earlier treatment
- The artery that caused the heart attack must have been successfully treated by PCI, with good blood flow. No major heart event (MACE) between the first PCI and the planned second procedure. No prior bypass surgery (CABG) and none planned.
Main reasons for not taking part
- Cardiogenic shock or very low blood pressure that does not respond to treatment
- Needs blood pressure drugs, a heart pump or other mechanical heart support, or is on a breathing tube
- Kidney function too low (CrCl below 30 ml/kg)
- Pregnant, or a woman who could become pregnant
- Cannot take dual antiplatelet therapy (DAPT) for at least 6 months
Read by machine on 12 November 2026.
Where in China
- Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, BeijingBeijing, ChinaContact: Lei Song, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- China National Center for Cardiovascular Diseases
- Trial code
- NCT05669222
- Record updated
- 24 September 2026
- Original description
The FAVOR V AMI study is a prospective, multicenter, blinded, randomized, sham-controlled trial comparing the long-term clinical outcomes of the "Functional and Angiography-derived Strain inTegration (FAST)" technique (next-generation quantitative flow ratio [μQFR] and radial wall strain [RWS]) guided percutaneous coronary intervention (PCI) strategy, with standard treatment strategy, in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD).Read full original descriptionShow less
Functional and Angiography-Derived Strain Guided Multi-Vessel/Lesion Revascularization Strategy in Patients With Acute ST-Segment Elevation Myocardial Infarction (FAVOR V AMI)
The FAVOR V AMI study is a prospective, multicenter, blinded, randomized, sham-controlled trial comparing the long-term clinical outcomes of the "Functional and Angiography-derived Strain inTegration (FAST)" technique (next-generation quantitative flow ratio [μQFR] and radial wall strain [RWS]) guided percutaneous coronary intervention (PCI) strategy, with standard treatment strategy, in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD).
Inclusion: General inclusion; Age ≥18 years; STEMI ≤30d; Successful primary PCI of all culprit lesion(s) responsible for the STEMI (visually-assessed residual stenosis <30% in stent-treated lesions or <50% in DCB-treated or PTCA-treated lesions, with TIMI-3 flow in all treated vessels); No MACE event between the index PCI and the staged randomized procedure; Able to understand the trial design and provide written informed consent; Angiographic inclusion:; The presence of at least 1 non-culprit lesion with DS% 50%-90% in any non-infarct related artery with RVD ≥2.5 mm by visual assessment; Non-culprit lesions are potentially eligible for PCI Note: All lesions in the infarct related arteries with DS ≥70% and RVD ≥2.5 mm by visual assessment must be successfully treated either during the index primary PCI or the staged procedure prior to randomization Note: There may also be 1 or more NCL with DS% >90% (including a CTO) as long as there is at least 1 NCL with DS% 50%-90% as above. Any such lesions in which PCI is intended must be treated successfully either during the index primary PCI or the staged procedure prior to randomization.
Exclusion: General exclusion; Cardiogenic shock or refractory hypotension (Killip IV); On pressors or use of or need for intra-aortic balloon pump or other mechanical circulatory support devices; Intubated; Prior thrombolytic therapy for this admission; Cockcroft-Gault-calculated CrCl <30 ml/kg; Pregnant or woman of child-bearing potential; Life expectancy less than 1 year for non-cardiac causes; Allergy to iodine-containing contrast agents which cannot be adequately premedicated; Unable to tolerate DAPT for at least 6 months; Prior CABG or planned CABG; Any planned surgery within 6 months; Any condition that may interfere with any follow-up procedures (e.g. dementia, drug use); Angiographic exclusion; Poor angiographic image quality precluding vessel contour detection or with suboptimal contrast opacification, branch ostium cannot be shown clearly, severe overlap in the stenosed segment or severe tortuosity of any interrogated vessel deemed not amenable to μQFR or RWS measurement; Unable to judge culprit lesion or infarct-related artery according to current evidence.